United States: FDA's Enforcement Priorities Likely To Change In 2017 And Other "Unknowable Knowns"

As we enter a new era in which executive agencies are headed by President Trump, we are also faced with many other transformative changes that will affect FDA-regulated entities in a significant and lasting way. This post will outline some of our thoughts related to what could face FDA and its various stakeholders as we go forward into the great unknown.

First, since being signed into law by President Obama on December 13th, we've been writing and speaking about the myriad provisions of the 21st Century Cures Act. This wide-ranging law has many mandates for agency actions and new guidance documents, which FDA will be working on beginning this year, but far beyond 2017 as well. Drug, biologic, and medical device stakeholders are also awaiting the outcome of the upcoming reauthorization of all the major User Fee Acts that are "must-pass" legislation before the end of the current fiscal year (FY17 ends on September 30th), in order to ensure FDA's continuing operations. Many other policy changes that are expected to result from the switch from a Democratic-led to a Republican-led Executive Branch, the latter also being supported by a GOP-controlled Congress, will likely have major impacts on medical product developers. 

A Disclaimer: Although as of today, without a definitive announcement from President-elect Trump about his pick to lead the Agency, it is somewhat difficult to make detailed predictions about what lies in store for FDA this year (or, for that matter, the next four years), we thought describing some trends and our general thoughts could be valuable. Some of these areas could be affected by the next FDA Commissioner, but it takes time and not an inconsiderable amount of buy-in from career Agency staff to make major changes in longstanding programs and initiatives, so less politically controversial issues are unlikely to be revisited in the short-term.

Regulations: When it comes to new regulations, it remains to be seen what steps Congress takes under the Congressional Review Act (see here and here) to roll back Final Rules promulgated since last May. But for any FDA regulations that remain in proposed rule form, don't lose sleep waiting for them to be finalized – one thing the incoming Administration has made clear is its disdain for "government regulation" writ large, and we expect that to translate into new leadership taking a hard look at everything that's currently in the pipeline.  Thus, some of the rules listed in the Agency's Fall 2016 Unified Regulatory Agenda as pending a proposed regulation are likely to be taken off the table altogether.

Guidance: For FDA guidance documents, which everyone refers to in order to understand the Agency's "thinking" even though technically they are non-binding on all parties, it is a simple matter for the next Commissioner to order individual centers and offices to withdraw either a Final Guidance or a Draft Guidance by providing written notice to affected parties in the Federal Register. Unlike final regulations, these documents are not subject to the notice-and-comment provisions of administrative law that require the same public consultation process to be undertaken for the rescission of regulations currently in effect.

So several of the more controversial or legally questionable guidance documents may be withdrawn by FDA following the change in leadership. One good example here would be the recent draft guidance that creates a quality metrics reporting program for pharmaceutical manufacturers, as that guidance was not well-received by industry. At the same time, however, we could see relatively fast action by the new FDA to issue guidance on certain subjects that current Agency leadership has delayed or been hesitant to act upon even with significant and diverse stakeholder pressure.  The prime example being guidance on the permissible scope of off-label communications by medical product manufacturers. Indeed, off-label communications and related enforcement are one area where we expect a significant policy change to be implemented by the Trump Administration.

Enforcement: Finally, some enforcement priorities and initiatives are likely to change in the near term as well.  Although it is unlikely that the next Administration will alter FDA's enforcement activities and policing of serious public safety issues – examples would be issuing safety communications when illegal drug residues are found in dietary supplement products, or sending Warning Letters when a compounding pharmacy is found to have insanitary operations – there may enter a more laissez-faire climate when it comes to enforcement of "victimless" regulatory violations. One area where this is likely would be in the enforcement of cosmetic labeling rules that do not allow cosmetic products to be labeled with claims that they can alter the structure or function of the skin or other parts of the body (because such claims would make the product a "drug" under the law). Over the past two years, FDA has markedly and aggressively increased its policing of these claims by issuing regulatory letters to manufacturers and requiring them to undertake corrective actions. In our view, those cosmetic enforcement actions are likely to be history, at least for now or until the political pendulum swings again.

There are some areas where we don't anticipate any changes, at least not noticeably for those of us outside of the Agency and looking in. For example, FDA has been busy implementing the Biologics Price Competition and Innovation Act and its new pathway for biosimilar products, as well as working with biosimilar developers and reviewing their marketing applications. This program is unlikely to see much attention from the Trump Administration, except perhaps to urge regulators to work more quickly and to help get more biosimilars to market. Similarly, the Agency as well as State regulators and affected industry alike have been working for years towards a food safety system for a modern, globalized supply chain in response to the Food Safety Modernization Act of 2011. So unraveling the complex and interlocking regulations that emerged from that food safety modernization process may be politically unpopular (assuming such an activity would not be administratively impossible, for all intents and purposes); only one of the seven major foundational Final Rules issued under FSMA falls within the window that would allow it to be considered for rescission under the Congressional Review Act. In general, therefore, we are not expecting a sea change in the area of foods.

It is also possible that President-elect Trump's seeming disdain for the outsourcing of drug manufacturing operations to countries like India and China will impact whether he would have his FDA Commissioner continue the high level of inspection activity of those facilities.  On the one hand, a large number of foreign manufacturing sites have been the subject of regulatory action (including some Import Alerts) due to their failure to comply with cGMPs and, in some cases, their use of outright fraudulent data in their quality systems. But on the other hand, ramping down inspections and regulatory actions makes it more difficult for those facilities to be given a clean bill of health by the Agency so that they can export products to the U.S., which would be equivalent to implementing a new regulatory policy through administrative inaction.

And we close with a shameless plug: As a reminder, for our readers in the New York region, please register to join us for our in-person presentation in our Manhattan offices on Tuesday, January 24th. The event will feature a discussion of the Agency's priorities for 2017, and the potential impact of the Trump administration on FDA regulated companies. Rodney Whitlock from ML Strategies will also discuss the expected health care activity generally in the 115th Congress. The 1-hour seminar kicks off at 5:30 pm and will be followed by a cocktail reception. We hope to see you there!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.